These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24072747)

  • 1. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
    Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
    Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
    Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
    Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
    Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
    J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ChK1 activation induces reactive astrogliosis through CIP2A/PP2A/STAT3 pathway in Alzheimer's disease.
    Zhou Y; Liu X; Ma S; Zhang N; Yang D; Wang L; Ye S; Zhang Q; Ruan J; Ma J; Wang S; Jiang N; Zhao Z; Zhao S; Zheng C; Fan X; Gong Y; Abdoul Razak MY; Hu W; Pan J; Wang X; Fan J; Li J; Liu R; Shentu Y
    FASEB J; 2022 Mar; 36(3):e22209. PubMed ID: 35195302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling.
    Hu W; Wang Z; Zhang H; Mahaman YAR; Huang F; Meng D; Zhou Y; Wang S; Jiang N; Xiong J; Westermarck J; Lu Y; Wang J; Wang X; Shentu Y; Liu R
    Neurotherapeutics; 2022 Mar; 19(2):570-591. PubMed ID: 35286657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
    Khanna A; Pimanda JE; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
    Nath S; Ohlmeyer M; Salathe MA; Poon J; Baumlin N; Foronjy RF; Geraghty P
    Am J Respir Cell Mol Biol; 2018 Dec; 59(6):695-705. PubMed ID: 30011381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
    Wang J; Okkeri J; Pavic K; Wang Z; Kauko O; Halonen T; Sarek G; Ojala PM; Rao Z; Xu W; Westermarck J
    EMBO Rep; 2017 Mar; 18(3):437-450. PubMed ID: 28174209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
    De P; Carlson J; Leyland-Jones B; Dey N
    Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway.
    Wang N; Zhou F; Guo J; Zhu H; Luo S; Cao J
    Life Sci; 2018 Sep; 209():498-506. PubMed ID: 30144452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
    Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
    Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.